Use of circulating tumour DNA to characterise the mutational landscape of marginal zone lymphoma, monitor treatment response and detect emergence of resistance

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1151560

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Marginal zone lymphoma (MZL) is a subtype of B-cell non-Hodgkin lymphoma for which the molecular drivers of disease are poorly understood. We hypothesise that circulating tumour DNA may be ideal for characterising the genetic mutations that underpin MZL, monitoring treatment response and detecting emergence of resistance. This non-invasive method of disease monitoring has the potential to transform management of cancers such as MZL, identify new treatment options and improve survival outcomes.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Postgraduate Scholarships

Funding Amount: $128,224.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Cell Biology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

DNA sequencing | biological markers | cancer genetics | cancer therapy | lymphoma

Related Links